Mirum Pharmaceuticals, Inc.
A pharmaceutical company focused on rare diseases, it markets three FDA-approved medicines: Livmarli for the severe itching of certain inherited liver conditions, Ctexli for cerebrotendinous xanthomatosis, and Cholbam for bile acid disorders. It was founded in 2018 by a team that revived its lead drug after pharmaceutical giant Shire set it aside, and its name comes from Latin, meaning "wonder" or "marvel."
Bought 131.4K
Granted 149.4K · Sold 94.0K
Granted 150.0K · Sold 150.0K
Granted 63.0K · Sold 24.7K
Granted 40.1K · Sold 24.3K
Granted 17.0K · Sold 17.0K
Granted 29.2K · Sold 16.0K
Granted 4.0K
Granted 4.0K
Granted 4.0K
Granted 13.5K · Sold 10.1K
Granted 38.0K · Sold 38.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Heron Patrick JDirector · 2 transactions | +7.8% | 4.03M | — | 131.4K | — |
| Peetz ChristopherCHIEF EXECUTIVE OFFICER, Director · 17 transactions | +5.7% | 409.2K | 149.4K | — | 94.0K |
| Grey Michael GDirector · 6 transactions | +17.8% | 330.2K | 150.0K | — | 150.0K |
| Radovich PeterPRESIDENT AND COO · 10 transactions | +206.7% | 57.3K | 63.0K | — | 24.7K |
| Bjerkholt EricCHIEF FINANCIAL OFFICER · 12 transactions | +51.3% | 47.2K | 40.1K | — | 24.3K |
| Brege LauraDirector · 3 transactions | +108.3% | 32.7K | 17.0K | — | 17.0K |
| Quan JoanneCHIEF MEDICAL OFFICER · 6 transactions | +233.9% | 18.9K | 29.2K | — | 16.0K |
| Fischer LaurentDirector · 1 transaction | +58.9% | 10.7K | 4.0K | — | — |
| Cardon LonDirector · 1 transaction | +69.7% | 9.7K | 4.0K | — | — |
| Walbert Timothy PDirector · 1 transaction | +69.7% | 9.7K | 4.0K | — | — |
| Howe JolandaSVP, GLOBAL CONTROLLER · 10 transactions | +140.5% | 5.8K | 13.5K | — | 10.1K |
| Ramasastry SairaDirector · 19 transactions | — | 0 | 38.0K | — | 38.0K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -242.7K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.